International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

For the three months ended September 30, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit.

Reconciliation of Selling and Administrative Expenses[1]

	Third Quarter	
(DOLLARS IN MILLIONS)	**2026**	**2025**
Reported (GAAP)	$ 387	$ 348
Divestiture Costs (c)	(10)	(11)
Strategic Initiatives Costs (f)	(9)	(9)
Regulatory Costs (g)	(34)	(6)
Other (i)	(3)	(2)
Adjusted (Non-GAAP)	$ 331	$ 320

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income (Loss) and EPS from Continuing Operations[1]

	Third Quarter							
	2026				2025			
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)	Income before taxes	(Benefit) Provision for income taxes (i)	Net income attributable to IFF	Diluted EPS	Income before taxes	(Benefit) Provision for income taxes (i)	Net income attributable to IFF	Diluted EPS
Reported (GAAP)	$ (134)	$ (7)	$ (127)	$ (0.50)	$ 130	$ 31	$ 99	$ 0.39
Restructuring and Other Charges (a)	5	1	4	0.01	14	3	11	0.04
Impairment of goodwill (b)	23	—	23	0.09	—	—	—	—
Divestiture Costs (c)	10	3	7	0.02	11	3	8	0.03
Gains on Business Disposals (d)	(2)	(1)	(1)	—	—	(1)	1	—
Losses on Assets Classified as Held for Sale (e)	236	48	188	0.73	—	—	—	—
Strategic Initiative Costs (f)	9	2	7	0.03	10	2	8	0.03
Regulatory Costs (g)	34	1	33	0.13	7	2	5	0.02
Entity Realignment Costs (h)	—	(12)	12	0.05	—	—	—	—
Other (i)	6	—	6	0.02	—	1	(1)	—
Adjusted (Non-GAAP)	$ 187	$ 35	$ 152	$ 0.58	$ 172	$ 41	$ 131	$ 0.51

Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization[1]

	Third Quarter	
(DOLLARS AND SHARE AMOUNTS IN MILLIONS)	2026	2025
Numerator		
Adjusted (Non-GAAP) Net Income	$ 152	$ 131
Amortization of Acquisition related Intangible Assets	78	84
Tax impact on Amortization of Acquisition related Intangible Assets (j)	19	20
Amortization of Acquisition related Intangible Assets, net of tax (k)	59	64
Adjusted (Non-GAAP) Net Income ex. Amortization	$ 211	$ 195
Denominator		
Weighted average shares assuming dilution (diluted)	254	257
Adjusted (Non-GAAP) EPS ex. Amortization	$ 0.83	$ 0.76

(a) For 2026 and 2025, represents costs primarily related to severance as part of the IFF Productivity Program.

(b) For 2026, represents the impairment of goodwill attributable to the Botanicals & Food Enhancements disposal group.

(c) For 2026 and 2025, primarily represents costs related to the Company's completed and anticipated divestitures, excluding external costs related to the planned divestiture of the Food Ingredients disposal group and the completed divestiture of the SCL disposal group. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

(d) For 2026, primarily represents gains recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business in 2025. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business.

(e) For 2026, represents the loss on assets classified as held for sale related to the Botanicals & Food Enhancements disposal group.

(f) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization.

(g) For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

(h) In 2025, the Company implemented a phased restructuring initiative aimed at optimizing its legal entity framework and recognized a one-time tax benefit. In 2026, the Company updated the tax benefit previously recorded.

(i) For 2026, represents the net impact of costs related to severance for certain executives who have separated from the Company, and losses recognized upon the sale of fixed assets.

(j) The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.

(k) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

For the nine months ended September 30, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit.

Reconciliation of Selling and Administrative Expenses[1]

	Third Quarter Year-to-Date	
(DOLLARS IN MILLIONS)	**2026**	**2025**
Reported (GAAP)	$ 1,158	$ 1,147
Divestiture Costs (c)	(25)	(88)
Strategic Initiatives Costs (f)	(27)	(23)
Regulatory Costs (g)	(115)	(70)
Entity Realignment Costs (i)	(2)	(5)
Other (j)	(2)	(6)
Adjusted (Non-GAAP)	$ 987	$ 955

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income (Loss) and EPS from Continuing Operations[1]

	Third Quarter Year-to-Date							
	2026				2025			
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)	Income before taxes	Provision (Benefit) for income taxes (k)	Net income attributable to IFF (l)	Diluted EPS	Income before taxes	Provision (Benefit) for income taxes (k)	Net income attributable to IFF (l)	Diluted EPS
Reported (GAAP)	$ 126	$ 65	$ 60	$ 0.23	$ 656	$ (61)	$ 716	$ 2.80
Restructuring and Other Charges (a)	15	4	11	0.04	49	11	38	0.15
Impairment of Goodwill (b)	23	—	23	0.09	34	—	34	0.13
Divestiture Costs (c)	25	5	20	0.08	88	37	51	0.20
(Gains) losses on Business Disposals (d)	(1)	(1)	—	—	111	(138)	249	0.97
Losses on Assets Classified as Held for Sale (e)	263	52	211	0.82	—	—	—	—
Strategic Initiative Costs (f)	27	6	21	0.08	24	5	19	0.07
Regulatory Costs (g)	115	4	111	0.43	71	17	54	0.21
Gain on debt extinguishment (h)	—	—	—	—	(488)	(116)	(372)	(1.45)
Entity Realignment Costs (i)	2	(11)	13	0.05	5	361	(356)	(1.40)
Other (j)	4	—	4	0.02	6	1	5	0.02
Adjusted (Non-GAAP)	$ 599	$ 124	$ 474	$ 1.84	$ 556	$ 117	$ 438	$ 1.70

Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization[1]

	Third Quarter Year-to-Date	
(DOLLARS AND SHARE AMOUNTS IN MILLIONS)	2026	2025
Numerator		
Adjusted (Non-GAAP) Net Income	$ 474	$ 438
Amortization of Acquisition related Intangible Assets	244	246
Tax impact on Amortization of Acquisition related Intangible Assets (k)	60	60
Amortization of Acquisition related Intangible Assets, net of tax (m)	184	186
Adjusted (Non-GAAP) Net Income ex. Amortization	$ 658	$ 624
Denominator		
Weighted average shares assuming dilution (diluted)	255	255
Adjusted (Non-GAAP) EPS ex. Amortization	$ 2.58	$ 2.45

(a) For 2026 and 2025, represents costs primarily related to severance as part of the IFF Productivity Program.

(b) For 2026, represents the impairment of goodwill attributable to the Botanicals & Food Enhancements disposal group. For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit that is not included in the Food Ingredients or SCL disposal groups.

(c) For 2026 and 2025, primarily represents costs related to the Company's completed and anticipated divestitures, excluding external costs related to the planned divestiture of the Food Ingredients disposal group and the completed divestiture of the SCL disposal group. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

(d) For 2026, primarily represents gains recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business in 2025. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business.

(e) For 2026, represents the loss on assets classified as held for sale related to the CitraSource business and the Botanicals & Food Enhancements disposal group.

(f) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization.

(g) For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

(h) For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of the tender offers.

(i) In 2025, the Company implemented a phased restructuring initiative aimed at optimizing its legal entity framework and recognized a one-time tax benefit. In 2026, the Company updated the tax benefit previously recorded.

(j) For 2026 and 2025, primarily represents the net impact of costs related to severance for certain executives who have separated from the Company. For 2026, also represents losses recognized upon the sale of fixed assets.

(k) The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.

(l) For each of the nine months ended September 30, 2026 and September 30, 2025, reported and adjusted net income from continuing operations are each decreased by income attributable to non-controlling interest from continuing operations of $1 million.

(m) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

International Flavors & Fragrances Inc.
Debt Covenants
(Amounts in millions)
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Credit Adjusted EBITDA to Net Income[1]

(DOLLARS IN MILLIONS)		Twelve Months Ended September 30, 2026
Net income	$	183
Interest expense		185
Income taxes		107
Depreciation and amortization		851
Specified items[2]		420
Non-cash items[3]		357
Credit Adjusted EBITDA	$	2,103

(1) Credit Adjusted EBITDA presented includes results from continuing and discontinued operations.

(2) Specified items consisted of restructuring and other charges, impairment of goodwill, divestiture costs, strategic initiatives costs, regulatory costs, and other costs that are not related to recurring operations.

(3) Non-cash items consisted of losses (gains) on business disposals, loss on assets classified as held for sale, and stock-based compensation.

Reconciliation of Net Debt to Total Debt

(DOLLARS IN MILLIONS)		September 30, 2026
Total debt[1]	$	6,307
Adjustments:		
Cash and cash equivalents		519
Net debt	$	5,788

(1) Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.

International Flavors & Fragrances Inc.
Comparable Currency Neutral Segment Performance
(Amounts in millions)
(Unaudited)

The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
Net Sales				
Taste[1]	$ 691	$ 654	$ 2,028	$ 1,948
Health & Biosciences	566	559	1,700	1,638
Scent[2]	691	650	1,963	1,867
Pharma Solutions[3]	—	—	—	—
Consolidated	$ 1,948	$ 1,863	$ 5,691	$ 5,453
Segment Adjusted Operating EBITDA[6]				
Taste[1]	$ 130	$ 122	$ 398	$ 358
Health & Biosciences	136	134	413	390
Scent[2]	138	125	396	378
Pharma Solutions[3]	—	—	—	—
Total	404	381	1,207	1,126
Depreciation & Amortization	(156)	(151)	(462)	(439)
Interest Expense	(46)	(48)	(136)	(180)
Other Expense, net	(14)	(13)	(47)	(52)
Restructuring and Other Charges	(5)	(14)	(15)	(49)
Impairment of Goodwill	(23)	—	(23)	(34)
Gains (Losses) on Business Disposals	2	—	1	(111)
Loss on Assets Classified as Held for Sale	(236)	—	(263)	—
Divestiture Costs	(10)	(11)	(25)	(88)
Strategic Initiative Costs	(9)	(10)	(27)	(24)
Regulatory Costs	(34)	(7)	(115)	(71)
Gain on Debt Extinguishment	—	—	—	488
Entity Realignment Costs	—	—	(2)	(5)
Other	(6)	—	(4)	(6)
Impact of Currency Fluctuations[4]	(1)	—	37	—
Impact of Business Divestitures[5]	—	3	—	101
Income from continuing operations before taxes	$ (134)	$ 130	$ 126	$ 656
Segment Adjusted Operating EBITDA Margin[5]				
Taste	18.8 %	18.7 %	19.6 %	18.4 %
Health & Biosciences	24.0 %	24.0 %	24.3 %	23.8 %
Scent	20.0 %	19.2 %	20.2 %	20.2 %
Consolidated	20.7 %	20.5 %	21.2 %	20.6 %

(1) Taste sales and segment adjusted operating EBITDA information exclude the results of the Rene Laurent business that was divested on December 1, 2025, to present fully comparable scenarios.

(2) Scent sales and segment adjusted operating EBITDA information exclude the results of the CitraSource business that was divested on July 1, 2026, to present fully comparable scenarios.

(3) Pharma sales and segment adjusted operating EBITDA information exclude the results of the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios.

(4) Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.

(5) Amounts exclude the results of the Rene Laurent business that was divested on December 1, 2025, the CitraSource business that was divested on July 1, 2026, and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios.

(6) Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Health & Biosciences, and Scent segments to align with the updated 2025 operating model.

	Nine Months Ended September 30, 2025	
	Selling & Administrative Expenses	Total EBITDA Impact
Taste	$ 6	$ (6)
Health & Biosciences	6	(6)
Scent	6	(6)
Total	$ 18	$ (18)

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
Comparable Foreign Exchange Impact
(Unaudited)

Q3 Taste	Sales	Segment Adjusted Operating EBITDA	Segment Adjusted Operating EBITDA Margin
% Change - Reported	4%	4%	(0.1)%
Portfolio Impact	1%	1%	0.0%
% Change - Comparable	5%	5%	(0.1)%
Currency Impact	1%	2%	0.2%
% Change - Currency Neutral	6%	7%	0.1%

Q3 Health & Biosciences	Sales	Segment Adjusted Operating EBITDA	Segment Adjusted Operating EBITDA Margin
% Change - Reported	1%	1%	0.0%
Portfolio Impact	0%	1%	0.1%
% Change - Comparable	1%	2%	0.1%
Currency Impact	0%	0%	0.0%
% Change - Currency Neutral	1%	2%	0.1%

Q3 Scent	Sales	Segment Adjusted Operating EBITDA	Segment Adjusted Operating EBITDA Margin
% Change - Reported	6%	9%	0.7%
Portfolio Impact	0%	2%	0.3%
% Change - Comparable	6%	11%	1.0%
Currency Impact	0%	(1)%	(0.2)%
% Change - Currency Neutral	6%	10%	0.8%

Q3 Consolidated	Sales	Adjusted Operating EBITDA	Adjusted Operating EBITDA Margin
% Change - Reported	4%	5%	0.3%
Portfolio Impact	0%	1%	0.0%
% Change - Comparable	4%	6%	0.3%
Currency Impact	1%	0%	(0.1)%
% Change - Currency Neutral	5%	6%	0.2%

Note: The sum of these items may not foot due to rounding.

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
Comparable Foreign Exchange Impact
(Unaudited)

YTD Taste	Sales	Segment Adjusted Operating EBITDA	Segment Adjusted Operating EBITDA Margin
% Change - Reported	5%	9%	0.9%
Portfolio Impact	0%	4%	0.4%
% Change - Comparable	5%	13%	1.3%
Currency Impact	(1)%	(2)%	(0.1)%
% Change - Currency Neutral	4%	11%	1.2%

YTD Health & Biosciences	Sales	Segment Adjusted Operating EBITDA	Segment Adjusted Operating EBITDA Margin
% Change - Reported	6%	8%	0.3%
Portfolio Impact	0%	1%	0.4%
% Change - Comparable	6%	9%	0.7%
Currency Impact	(2)%	(3)%	(0.2)%
% Change - Currency Neutral	4%	6%	0.5%

YTD Scent	Sales	Segment Adjusted Operating EBITDA	Segment Adjusted Operating EBITDA Margin
% Change - Reported	7%	7%	(0.1)%
Portfolio Impact	0%	3%	0.5%
% Change - Comparable	7%	10%	0.4%
Currency Impact	(2)%	(5)%	(0.4)%
% Change - Currency Neutral	5%	5%	0.0%

YTD Consolidated	Sales	Adjusted Operating EBITDA	Adjusted Operating EBITDA Margin
% Change - Reported	(1)%	1%	0.4%
Portfolio Impact	7%	9%	0.3%
% Change - Comparable	6%	10%	0.7%
Currency Impact	(2)%	(3)%	(0.2)%
% Change - Currency Neutral	4%	7%	0.5%

Note: The sum of these items may not foot due to rounding.